+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Aptevo Therapeutics Inc (APVO) - Financial and Strategic SWOT Analysis Review

Aptevo Therapeutics Inc (APVO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Aptevo Therapeutics Inc (Aptevo) is a clinical-stage biotechnology company focused on the research and development of novel immunotherapy candidates for cancer treatment. It is developing innovative immunotherapy candidates for cancer treatment using its Adaptir and Adaptir-Flex platforms that enable the creation of monospecific, bispecific, and multispecific immunotherapeutic proteins to enhance or regulate immune responses. Aptevo's major products include clinical candidates mipletamig and ALG.APV-527, as well as several preclinical candidates, including APVO603, a dual agonist that targets both 4-1BB and OX40; APVO442, which is designed for prostate cancer; and APVO711, which stimulates CD40 while inhibiting the PD-1/PD-L1 pathway. Its products are designed for applications in oncology, targeting various forms of cancer. The company collaborates with partners such as Alligator Bioscience for the development of certain therapies. Aptevo is headquartered in Seattle, Washington, the US.

Aptevo Therapeutics Inc Key Recent Developments

  • Sep 24, 2026: Aptevo Advances Trispecific Candidate Toward Clinical Development
  • Aug 14, 2026: Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
  • Aug 14, 2026: Aptevo Therapeutics Inc. Files SEC Form 8-K
  • Jun 30, 2026: Aptevo Receives $1.5 Million Non-Dilutive Grant From Andy Hill CARE Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Aptevo Therapeutics Inc - Key Facts
  • Aptevo Therapeutics Inc - Key Employees
  • Aptevo Therapeutics Inc - Key Employee Biographies
  • Aptevo Therapeutics Inc - Major Products and Services
  • Aptevo Therapeutics Inc - History
  • Aptevo Therapeutics Inc - Company Statement
  • Aptevo Therapeutics Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Aptevo Therapeutics Inc - Business Description
  • R&D Overview
  • Aptevo Therapeutics Inc - Corporate Strategy
  • Aptevo Therapeutics Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • Aptevo Therapeutics Inc - Strengths
  • Aptevo Therapeutics Inc - Weaknesses
  • Aptevo Therapeutics Inc - Opportunities
  • Aptevo Therapeutics Inc - Threats
  • Aptevo Therapeutics Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Aptevo Therapeutics Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Sep 24, 2026: Aptevo Advances Trispecific Candidate Toward Clinical Development
  • Aug 14, 2026: Aptevo Therapeutics Inc. Files SEC Form 8-K
  • Aug 14, 2026: Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
  • Jun 30, 2026: Aptevo Receives $1.5 Million Non-Dilutive Grant From Andy Hill CARE Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
  • May 28, 2026: Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
  • May 13, 2026: Aptevo Therapeutics Provides Q1 2026 Business Update; RAINIER On Track for 2026 Completion and Phase 2 Dose Selection
  • Mar 26, 2026: Aptevo Reports Business Update and 2025 Financial Results
  • Mar 26, 2026: Aptevo Provides State of the Business Report and 2025 Financial Results
  • Mar 19, 2026: Aptevo to Participate in March 2026 Conferences
  • Feb 03, 2026: Aptevo Announces Executive Leadership Transitions to Support Next Phase of Growth
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Analyst
  • Contact Us
  • Disclaimer
List of Tables
  • Aptevo Therapeutics Inc, Key Facts
  • Aptevo Therapeutics Inc, Key Employees
  • Aptevo Therapeutics Inc, Key Employee Biographies
  • Aptevo Therapeutics Inc, Major Products and Services
  • Aptevo Therapeutics Inc, History
  • Aptevo Therapeutics Inc, Subsidiaries
  • Aptevo Therapeutics Inc, Key Competitors
  • Aptevo Therapeutics Inc, Ratios based on current share price
  • Aptevo Therapeutics Inc, Annual Ratios
  • Aptevo Therapeutics Inc, Interim Ratios
  • Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2020 to YTD 2026
  • Aptevo Therapeutics Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Aptevo Therapeutics Inc, Performance Chart (2021 - 2025)
  • Aptevo Therapeutics Inc, Ratio Charts
  • Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2020 to YTD 2026
  • Aptevo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2020 to YTD 2026

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Regeneron Pharmaceuticals Inc
  • MacroGenics Inc
  • Gilead Sciences Inc
  • Genmab AS
  • Bristol-Myers Squibb Co
  • Amgen Inc
  • AbbVie Inc